GREENWICH, Conn.–(BUSINESS WIRE)–Soleus Capital Management, L.P., a healthcare investment firm which owns in excess of 10% of the stock of Theratechnologies Inc. (NASDAQ: THTX), today sent a letter to the Board of Directors of the Company.
In its letter, Soleus Capital described its belief that an acquisition of the Company is in the best interest of the Company’s shareholders and urged the Board to pursue an acquisition offer announced earlier today by Future Pak, LLC at a price of at least $3.51 per share, representing a premium of at least 163% to the closing price of the Company on April 10th.
The letter also described Soleus Capital’s concern that management of the Company and the Board had repeatedly ignored and/or been unresponsive to potential interested parties who have reached out to Company management for the purpose of entering into acquisition talks, which is inconsistent with management’s and the Board’s obligations to shareholders.
Soleus stated that, given the significant premium and all-cash nature of the Future Pak offer, significantly more value would accrue to shareholders by accepting the offer rather than continuing as a standalone company or in any potential alternative combination which prioritizes management job preservation over shareholder value.
The full letter is available via this link: Letter to The Board
About Soleus Capital
Soleus Capital is a healthcare investment firm located in Greenwich, CT which manages hedge, private equity and credit funds primarily focused on the innovative areas of life sciences, including biotech, medtech, diagnostics, and genomics.
